Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

1. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. (PubMed)

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources

2019 Cochrane

2. ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors Jill S. Goldman, MS, MPhil 1,2 , Susan E. Hahn, MS 3 , Jennifer Williamson Catania, MS, MPH 1,2 , Susan LaRusse-Eckert, MS 2 , Melissa (...) the following considerations in reaffirming this document: 1. To use the phrase “pathogenic variant” rather than the word “mutation” in discussing pathogenic variants related to autosomal dominant early-onset Alzheimer disease. This would be consistent with current ACMG/AMP Guidelines for Variant Interpretation and Reporting 1 . 2. Because this document no longer meets the criteria for an evidence-based practice guideline by either the American College of Medical Genetics and Genomics (ACMG) or National

2019 American College of Medical Genetics and Genomics

3. Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial

Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial Our study aimed to assess the effect of a 12-month vitamin D supplementation on cognitive function and amyloid beta (Aβ)-related biomarkers in subjects with Alzheimer's disease (AD). METHODS : This was a randomised, double-blind, placebo-controlled trial. 210 AD patients were randomly divided

2019 EvidenceUpdates

4. Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow

Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Prescrire IN ENGLISH - Spotlight ''Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow'', 1 May 2019 {1} {1} {1} | | > > > Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow A study conducted by the independent French medical journal Prescrire shows a reduction of only around 26% in the number of patients in France exposed to at least one Alzheimer's disease drug between 2012 and 2017. In approximately 3 out of 4 newly exposed patients, treatment lasted for more than 6 months, despite the proven harms. In France, as far back as 2011, the pharmacoeconomic committee

2019 Prescrire

5. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened (...) carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score

2019 EvidenceUpdates

6. Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A Prospective Cohort Study. (PubMed)

Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A Prospective Cohort Study. Decreased scam awareness may be an early indicator of impending Alzheimer dementia and its precursor, mild cognitive impairment, but prior studies have not systematically examined the associations between scam awareness and adverse cognitive outcomes.To test the hypothesis that low scam awareness is associated with increased risk for incident Alzheimer dementia, mild cognitive (...) impairment, and Alzheimer disease pathology in the brain.Prospective cohort study of aging.Community-based study in the greater Chicago metropolitan area.935 older persons initially free of dementia.Scam awareness was measured via questionnaire, incident Alzheimer dementia and mild cognitive impairment were documented in detailed annual cognitive and clinical evaluations, and Alzheimer disease neuropathology was quantified after death among a subset of persons who died (n = 264). Proportional hazards

2019 Annals of Internal Medicine

7. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. (PubMed)

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due (...) to Alzheimer's disease.We conducted a randomized, double-blind, placebo-controlled, 104-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia. The primary outcome was the change from baseline to week 104 in the score on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores

2019 NEJM

8. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. (Full text)

Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.Nationwide case-control study.Finnish national population and drug register, between 1999 and 2013.All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician (...) , and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60

2019 BMJ PubMed

9. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT

Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2019 NIHR HTA programme

10. Systematic review of mortality and prevalence rates from Alzheimer's disease and associated sociodemographic variables

Systematic review of mortality and prevalence rates from Alzheimer's disease and associated sociodemographic variables Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

11. Systematic review and meta-analysis of associations between subjective cognitive decline and biomarkers of Alzheimer's disease

Systematic review and meta-analysis of associations between subjective cognitive decline and biomarkers of Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

12. Racial / ethnic differences in Alzheimer's disease and dementia risk in the United States: a systematic review and meta-analysis

Racial / ethnic differences in Alzheimer's disease and dementia risk in the United States: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

13. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease

A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

14. A meta analysis of TCM kidney-nourishing formula in comparison with donepezil in the treatment of Alzheimer's disease

A meta analysis of TCM kidney-nourishing formula in comparison with donepezil in the treatment of Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

15. A systematic review of clinical trials assessing the effects of interventions inducing nutritional ketosis on Alzheimer's disease (AD) indicators

A systematic review of clinical trials assessing the effects of interventions inducing nutritional ketosis on Alzheimer's disease (AD) indicators Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

16. Systematic search and review on the use of language-focused interventions for the treatment of language deficits in Alzheimer's disease

Systematic search and review on the use of language-focused interventions for the treatment of language deficits in Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

17. Risk factors for apathy and its prognosis in Alzheimer's disease: a systematic review

Risk factors for apathy and its prognosis in Alzheimer's disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

18. What are the neural correlates of meta-cognition and insight in Alzheimer's Disease? A systematic review

What are the neural correlates of meta-cognition and insight in Alzheimer's Disease? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

19. Quality-adjusted life years in Alzheimer's Disease: a systematic review

Quality-adjusted life years in Alzheimer's Disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

20. Interventions to enhance sleep in mild cognitive impairment (MCI) and early / mild Alzheimer's dementia

Interventions to enhance sleep in mild cognitive impairment (MCI) and early / mild Alzheimer's dementia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO